Cost-effectiveness of dostarlimab plus chemotherapy for primary advanced or recurrent endometrial cancer
ObjectiveIn the double-blind, phase III, placebo-controlled RUBY randomized clinical trial, dostarlimab plus carboplatin-paclitaxel significantly increased survival among patients with primary advanced or recurrent endometrial cancer (EC). We conducted a cost-effectiveness analysis of dostarlimab in...
Збережено в:
| Автори: | , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
Frontiers Media S.A.
2024-06-01
|
| Серія: | Frontiers in Pharmacology |
| Предмети: | |
| Онлайн доступ: | https://www.frontiersin.org/articles/10.3389/fphar.2024.1391896/full |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|